| 产品名称 | Peptides EP05802_1 | PRAME 100-108 (HLA-A*02:01) |
|---|---|
| 目录号 | EP05802_1 |
| 别名 | PRAME 100-108 (HLA-A*02:01) |
| 外观 | 见COA |
| 分子量 | N/A |
| CAS | N/A |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
| 目录号 | 规格 | 价格 | 库存状态 | |
| EP05802_1 | 1 mg; 5 mg | 咨询 | 咨询 |
Peptides EP05802_1 | PRAME 100-108 (HLA-A*02:01)
品名：PRAME 100-108 (HLA-A*02:01)
货号：EP05802_1
规格：1 mg; 5 mg
品牌：Peptides.de
产品描述
The PRAME 100-108 peptide with the amino acid sequence VLDGLDVLL is a linear epitope (epitope ID 869501) derived from the Preferentially Expressed Antigen in Melanoma (PRAME, UniProt:P78395). It is used to stimulate human Prame (100-108)-specific CD8+T cells. PRAME belongs to the cancer/testis antigens in Homo sapiens. This antigen is notably overexpressed in various solid tumors, including melanoma, epithelial ovarian cancer, multiple sarcoma subtypes, and non-small cell lung cancer, while its expression in healthy tissues is mostly restricted to the testes. The PRAME 100-108 (VLDGLDVLL) epitope is presented by the MHC class I HLA-A*02:01 allele and was initially identified by Kessler et al. in 2001. In their studies, they demonstrated that cytotoxic T lymphocytes, which recognize this high-affinity binding epitope, could specifically target and lyse melanoma, lung, mammary, renal cell and cervical cancer cell lines.
| Protein | Melanoma antigen preferentially expressed in tumors |
| Species | Human |
| Application | Flow Cytometry |
| Indication | Cancer |
